RemeGen Co (SHSE:688331) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688331 RemeGen Co Ltd SHSE:688331
44 GF Score
Price ¥113.05
GF Value ¥276.84
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is RemeGen Co FFO?

FFO (Funds from operations) only applies to REITs.

SHSE:688331
44GF Score
RemeGen Co Ltd SHSE:688331
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is RemeGen Co (SHSE:688331) Overvalued in 2026?

Based on GuruFocus' analysis, RemeGen Co stock appears to be undervalued. The current stock price of ¥113.05 is trading 59.2% below its estimated GF Value™ of ¥276.84. GuruFocus considers RemeGen Co to be Modestly Undervalued.

Key valuation signals for SHSE:688331:

  • FFO:
  • GF Value™: ¥276.84 vs. price of ¥113.05 (59.2% below fair value)
  • GF Score™: 44/100 with 6 warning signs

No single metric tells the full story. See the SHSE:688331 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


RemeGen Co Business Description

Address 58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
44GF Score

Get the complete analysis for SHSE:688331

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥113.05
Price
¥276.84
GF Value